Quality by Design - SAAPIsaapi.org.za/wp-content/uploads/2014/05/Dr-Zahn-Quality-by-Design.… ·...
Transcript of Quality by Design - SAAPIsaapi.org.za/wp-content/uploads/2014/05/Dr-Zahn-Quality-by-Design.… ·...
Quality by Design
SAAPI Conference
Pretoria, 13 April 2016
Manuel Zahn
Road Map to Robust Manufacturing
Perform risk assessment;
Target the product profile;
Identify critical quality attributes;
Define a design space for manufacturing;
Implement a control strategy;
Manage product lifecycle / continuous improvement.
© 3R Pharma Consulting GmbH – Slide # 2
Principles
Risk Based Orientation
Quality should be built into the product;
Testing alone cannot be relied on to ensure product quality.
"Quality should be produced - not tested"
© 3R Pharma Consulting GmbH – Slide # 3
Today: Low Process Capability
Scrap and rework at 5-10% is accepted;
Time to ‘effectiveness’ is not challenged;
Cost of Quality > 20%
On time supply 60-80%
Right First Time 85-95%
2.5 sigma processes.
© 3R Pharma Consulting GmbH – Slide # 4
Product Quality and Process Sigma
Sigma (σ) ppm Defect Yield Cost of Quality
2 308537 69.2% 25-35%
3 66807 93.4% 20-25%
4 6210 99.4% 12-18%
5 233 99.98% 4-8%
6 3.4 99.99966% 1-3%
Source: Ali Afnan, Office of Pharmaceutical Science, CDER, FDAConcept Heidelberg, 24 Oct 2007
© 3R Pharma Consulting GmbH – Slide # 5
PROCESS ANALYTICAL TECHNOLOGY (PAT)
FDA Definition
A system for designing, analyzing, and controlling manufacturing
through timely measurements (i.e., during processing) of critical quality and performance attributes of raw and in-process materials and processes,
with the goal of ensuring final product quality.
© 3R Pharma Consulting GmbH – Slide # 7
The Desired State of Manufacturing
Product quality and performance are ensured through the design of effective and efficient manufacturing processes;
Product and process specifications are based on a mechanistic understanding of how formulation and process factors affect product performance;
Continuous real time quality assurance.
© 3R Pharma Consulting GmbH – Slide # 8
PAT Approach
Source: Dr. Gabriele Reich, IPMB – University of Heidelberg
© 3R Pharma Consulting GmbH – Slide # 9
PAT is a Philosophy ...
... rather than a set of instruments or a new measurement technology.
Continuous quality assurance;
Flexibility based on science;
Process understanding / risk management;
Part of GMP for the 21st century
Source: Dr. Gabriele Reich, IPMB – University of Heidelberg
© 3R Pharma Consulting GmbH – Slide # 10
DESIGN OF EXPERIMENTS
Sir Ronald Aylmer Fisher
Born 17 Feb 1890 in London
Invented "Design of Experiments" in the 1920s and 1930s at an agricultural research station north of London.
Agricultural experiments with natural fluctuations (temperature, soil condition, rain fall)
1935: 1st edition of his textbook "The Design of Experiments"
Died 29 July 1962 in Australia
DoE Applications
1948-1956, George E. P. Box optimized chemical processes at ICI (married one of Ron Fisher's five daugthers);
In the 1950s, Genichi Taguchi (Toyota) developed the use of an outer arrayfor factors that are uncontrollable in real life to improve the quality of manufactured goods ;
late 1970s: "Total Quality", "Six Sigma" programs(Motorola, GE, etc.).
© 3R Pharma Consulting GmbH – Slide # 13
DoE Definition
= A series of tests in which purposeful changes are made to the input variables of a system or process, and the effects on response variables are measured.
Maximizing the amount of information gained from a study while minimizing the amount of data to be collected.
Source:
Jacqueline K. Telford, Johns Hopkins APL Technical Digest, Vol 27 (3), 224-232 (2007)
© 3R Pharma Consulting GmbH – Slide # 14
DoE Benefits
Reduce time to design/develop new products & processes;
Increase process understanding;
Improve performance of processes;
Achieve product & process robustness;
Improve reliability and performance of products;
etc.
© 3R Pharma Consulting GmbH – Slide # 15
General Model of a Process or System
© 3R Pharma Consulting GmbH – Slide # 16
Examples
Process:
Granulation
Inputs:
API + excipients
Factors (variables):
Mixing time, stirrer speed, water temperature
Outputs (responses):
Content uniformity, degradation, water content
© 3R Pharma Consulting GmbH – Slide # 17
Factorial Designs
Investigate the effects of many different factors by varying them simultaneously;(p = number of factors)
Collect data at two levels (high & low);(+1 and ‒1)
Full factorial design requiring 2p runs.
© 3R Pharma Consulting GmbH – Slide # 18
Full & Fractional Factorial Designs
p = 3runs: 23 = 8
p = 3runs: 23 ∙ (½) = 4
full 1/2
Runs required: 2p-q
© 3R Pharma Consulting GmbH – Slide # 19
Example
Process:
Crystallisation
Inputs:
Substance A, Water, n-Heptane
Factors (variables):
Equivalents of Substance A
Concentration of A in Water
Ratio of Water to n-Heptane
Temperature during isolation/washing
Outputs (responses):
Yield, assay, impurities
© 3R Pharma Consulting GmbH – Slide # 20
Example: Fractional Factorial Design
Run Substance A
Concentration of A in Water
Ratio of Water to n-Heptane
Temperature
1 −1 −1 −1 −1
2 −1 −1 +1 +1
3 −1 +1 −1 +1
4 −1 +1 +1 +1
5 +1 −1 −1 −1
6 +1 −1 +1 +1
7 +1 +1 −1 −1
8 +1 +1 +1 +1
p = 4runs: 24 ∙ (½) = 8
© 3R Pharma Consulting GmbH – Slide # 21
Plot of Yield vs. Concentration of Substance A in Water
Substance A
Water
Optimum Yield
© 3R Pharma Consulting GmbH – Slide # 22
Plot of Yield vs. Solvent Ratio and Amount of Substance A
Substance A
Optimum Yield
© 3R Pharma Consulting GmbH – Slide # 23
Plot of Yield vs. Temperature and Solvent Ratio
Optimum Yield
© 3R Pharma Consulting GmbH – Slide # 24
Results of the DoE
Proven Acceptable Range (PAR)useful knowledge about the process,operation within this range will result in producing a material meeting relevant quality criteria;
Critical Process Parameter (CPP)should be monitored or controlled to ensure the process produces the desired quality;
Critical Quality Attribute (CQA)should be within an appropriate limit, range, or distribution to ensure the desired product quality.
ICH Q8(R2) - Pharmaceutical Development - Aug 2009
© 3R Pharma Consulting GmbH – Slide # 25
"The statistician cannot evade the responsibility for understanding the process
he applies or recommends."Ron Fisher
© 3R Pharma Consulting GmbH – Slide # 26
DESIGN SPACE
Design Space
=The multidimensional combination and interaction of input variables (e.g., material attributes) and process parameters that have been demonstrated to provide assurance of quality (ICH Q8).
Working within the design space is not considered as a change. Movement out of the design space is considered to be a change and would normally initiate a regulatory post approval change process.
Design space is proposed by the applicant and is subject to regulatory assessment and approval.
© 3R Pharma Consulting GmbH – Slide # 28
Knowledge SpaceWhere we have experience
Design SpaceWhere we are good
© 3R Pharma Consulting GmbH – Slide # 29
Presentations of Design Space
Source: ICH Q8
Parameters 1 and 2 are factors of a granulation operation that affect the dissolution rate of a tablet (e.g., excipient attribute, water amount, granule size.)
Surface plot Contour plot
© 3R Pharma Consulting GmbH – Slide # 30
Design space determined from the common region of multiple CQAs
Source: ICH Q8© 3R Pharma Consulting GmbH – Slide # 31
The drying operation is dependent upon the path of temperature over time. The end point for moisture content is 1-2%.
Source: ICH Q8
Design Space for a Drying Operation
© 3R Pharma Consulting GmbH – Slide # 32
© 3R Pharma Consulting GmbH – Slide # 33
Thank You
3R Pharma Consulting GmbHDr. Manuel ZahnWildbader Str. 375335 Dobel Germanywww.3rpc.com
© 3R Pharma Consulting GmbH – Slide # 34